P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

Lignende værker

• P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
  af: Philippe Moreau, et al.
  Udgivet: (2023-08-01)
• P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON
  af: M. Delforge, et al.
  Udgivet: (2022-06-01)
• PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON
  af: L. Rosinol, et al.
  Udgivet: (2022-06-01)
• PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
  af: A. Krishnan, et al.
  Udgivet: (2022-06-01)
• P42 | COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALITEC VS. REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN LOCOMMOTION AND MOMMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA
  af: A. Perrot, et al.
  Udgivet: (2026-04-01)